Logo image of IMVT

IMMUNOVANT INC (IMVT) Stock Price, Quote, News and Overview

NASDAQ:IMVT - Nasdaq - US45258J1025 - Common Stock - Currency: USD

23.05  -0.35 (-1.5%)

After market: 23.05 0 (0%)

IMVT Quote, Performance and Key Statistics

IMMUNOVANT INC

NASDAQ:IMVT (1/24/2025, 5:20:02 PM)

After market: 23.05 0 (0%)

23.05

-0.35 (-1.5%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High39.55
52 Week Low22.41
Market Cap3.38B
Shares146.78M
Float62.23M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)02-10 2025-02-10/amc
IPO05-14 2019-05-14


IMVT short term performance overview.The bars show the price performance of IMVT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

IMVT long term performance overview.The bars show the price performance of IMVT in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100 150 200

The current stock price of IMVT is 23.05 USD. In the past month the price decreased by -10.52%. In the past year, price decreased by -39.74%.

IMMUNOVANT INC / IMVT Daily stock chart

IMVT Latest News, Press Releases and Analysis

News Image
5 hours ago - Kuehn Law, PLLC

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT)...

News Image
a month ago - Market News Video

RSI Alert: Immunovant (IMVT) Now Oversold

News Image
3 months ago - Immunovant Inc.

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept...

News Image
3 months ago - Immunovant Inc.

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for...

News Image
4 months ago - Investor's Business Daily

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases

Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.

IMVT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 15.84 300.94B
AMGN AMGEN INC 14.33 148.05B
GILD GILEAD SCIENCES INC 21.01 115.99B
VRTX VERTEX PHARMACEUTICALS INC 862 113.22B
REGN REGENERON PHARMACEUTICALS 14.88 74.26B
ARGX ARGENX SE - ADR N/A 38.80B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 35.95B
BNTX BIONTECH SE-ADR N/A 28.47B
ONC BEIGENE LTD-ADR N/A 23.64B
NTRA NATERA INC N/A 22.13B
BIIB BIOGEN INC 8.95 21.30B
SMMT SUMMIT THERAPEUTICS INC N/A 17.52B

About IMVT

Company Profile

IMVT logo image Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. The company is headquartered in New York City, New York and currently employs 207 full-time employees. The company went IPO on 2019-05-14. The firm is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. The company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.

Company Info

IMMUNOVANT INC

320 West 37Th Street

New York City NEW YORK 10018 US

CEO: Peter Salzmann

Employees: 207

Company Website: https://immunovant.com/

Investor Relations: https://www.immunovant.com/investors

Phone: 19175803099

IMVT FAQ

What is the stock price of IMVT?

The current stock price of IMVT is 23.05 USD.


What is the symbol for IMMUNOVANT INC stock?

The exchange symbol of IMMUNOVANT INC is IMVT and it is listed on the Nasdaq exchange.


On which exchange is IMVT stock listed?

IMVT stock is listed on the Nasdaq exchange.


Is IMVT a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for IMVT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of IMVT.


Does IMVT stock pay dividends?

IMVT does not pay a dividend.


When does IMVT stock report earnings?

IMVT will report earnings on 2025-02-10, after the market close.


What is the Price/Earnings (PE) ratio of IMVT?

IMVT does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.22).


What is the Short Interest ratio of IMVT stock?

The outstanding short interest for IMVT is 19.7% of its float.


IMVT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

IMVT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to IMVT. While IMVT has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IMVT Financial Highlights

Over the last trailing twelve months IMVT reported a non-GAAP Earnings per Share(EPS) of -2.22. The EPS decreased by -12.69% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -62.63%
ROE -71.93%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-64.44%
Sales Q2Q%N/A
EPS 1Y (TTM)-12.69%
Revenue 1Y (TTM)N/A

IMVT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 88% to IMVT. The Buy consensus is the average rating of analysts ratings from 20 analysts.


Ownership
Inst Owners50.32%
Ins Owners1.52%
Short Float %19.7%
Short Ratio13.66
Analysts
Analysts88
Price Target51.17 (122%)
EPS Next Y-51.88%
Revenue Next YearN/A